Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02365441
Registration number
NCT02365441
Ethics application status
Date submitted
4/11/2014
Date registered
19/02/2015
Date last updated
7/07/2023
Titles & IDs
Public title
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Query!
Scientific title
A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Query!
Secondary ID [1]
0
0
ACTRN12614000950662
Query!
Secondary ID [2]
0
0
AG1013GST
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ALT GIST
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastrointestinal Stromal Tumour
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Stomach
Query!
Cancer
0
0
0
0
Query!
Bowel - Small bowel (duodenum and ileum)
Query!
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Regorafenib
Treatment: Drugs - imatinib
Active Comparator: Arm A - imatinib 400mg orally daily continuously
Experimental: Arm B - alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
Treatment: Drugs: Regorafenib
Treatment: Drugs: imatinib
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective tumour response (complete or partial response) as determined by RECIST v1.1
Query!
Assessment method [1]
0
0
The objective tumour response rate (OTRR) will be calculated by summing the number of participants assessed as having a complete or partial response within the first 9 months from the time from either (i) randomization (if patients have not yet commenced treatment) or (ii) commencement of therapy (if patients are randomized during the first cycle of imatinib), and dividing this by the total number of participants evaluable for response. For patients who undergo surgery, the best response is determined in the time period that precedes the date of surgery. The responses are confirmed at the time of the next scheduled imaging, usually done 8 weeks after the first detection of response, provided that imaging of the target lesions is not indicated sooner than this for other reasons. Both the numbers and the proportions of confirmed and unconfirmed responses will be reported. The minimum duration of SD is defined as 8 weeks.
Query!
Timepoint [1]
0
0
At or before 9 months from the time from either (i) randomization (if patients have not yet commenced treatment) or (ii) commencement of therapy (if patients are randomized during the first cycle of imatinib)
Query!
Secondary outcome [1]
0
0
Progression free survival at 24 months (disease progression or death)
Query!
Assessment method [1]
0
0
PFS at 24 months as calculated from the time from either (i) randomization if patients have not yet commenced treatment) or (ii) commencement of therapy (if patients are randomized during the first cycle of imatinib) to the date of progression as determined by RECIST v1.1
Query!
Timepoint [1]
0
0
24 Months
Query!
Secondary outcome [2]
0
0
Clinical benefit rate at 24 weeks
Query!
Assessment method [2]
0
0
Clinical benefit rate (SD + PR + CR) following 2 cycles of treatment
Query!
Timepoint [2]
0
0
24 weeks
Query!
Secondary outcome [3]
0
0
Time to treatment failure
Query!
Assessment method [3]
0
0
Time to treatment failure is defined as the time from either (i) randomization (if patients have not yet commenced treatment) or (ii) commencement of therapy (if patients are randomized during the first cycle of imatinib) to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.
Query!
Timepoint [3]
0
0
5 years
Query!
Secondary outcome [4]
0
0
Adverse Events
Query!
Assessment method [4]
0
0
Safety/toxicity/tolerability
Query!
Timepoint [4]
0
0
5 years
Query!
Secondary outcome [5]
0
0
Overall survival
Query!
Assessment method [5]
0
0
Overall survival is defined as the interval from either (i) randomization (if patients have not yet commenced treatment) or (ii) commencement of therapy (if patients are randomized during the first cycle of imatinib) to date of death from any cause, or the date of last known follow-up alive.
Query!
Timepoint [5]
0
0
5 years
Query!
Eligibility
Key inclusion criteria
- Adults (over 18 yrs) with histologically confirmed GIST. In CD-117-negative cases
DOG-1 must be positive or a KIT/PDGFRA mutation must be present.
- Unresectable, metastatic disease.
- No prior TKI for metastatic disease, with the exception of those patients who have had
up to 21 days of uninterrupted treatment on 400mg daily of imatinib.
- Imatinib therapy given as an adjuvant treatment and completed at least 3 months prior
to entry into this trial is permitted. Patients who have progression of GIST while on
adjuvant therapy are not eligible for this trial.
- ECOG performance status 0-2
- Measurable disease by RECIST version 1.1. (Note: Participants with only peritoneal
disease will be eligible only if they have lesions measurable in two dimensions and
have at least 1 lesion which is = 2 cm in size).
- Adequate bone marrow function (Haemoglobin = 9.0g/dL, platelet count = 100 x 109/L,
and absolute neutrophil count = 1.5 x 109/L).
- Adequate liver function (Serum total bilirubin =1.5 x ULN, INR = 1.5, and ALT, AST,
ALP =2.5 x ULN (= 5 x ULN for participants with liver metastases). Lipase level must
be = 1.5 x ULN.
- Adequate renal function (Creatinine clearance > 50ml/min) based on either the
Cockcroft Gault formula, 24 hour urine or Glomerular Filtration Rate (GFR scan); and
serum creatinine = 1.5 x ULN.
- Tumour tissue available for central review.
- Willing and able to comply with all study requirements, including treatment timing
and/or nature of required assessments.
- Study treatment both planned and able to start within 14 days of randomisation.
- Signed, written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Concurrent GI illness which may prevent absorption of imatinib or regorafenib - please
note that prior gastrectomy or bowel resection does not exclude patients from this
study.
- Use of other investigational drugs within 4 weeks prior to enrolment.
- Known sensitivity to any of the study drugs, study drug classes, or excipients in the
formulation.
- Participants receiving therapeutic doses of warfarin.
- Presence of brain metastases.
- The presence of PDGFR D842V mutation or other mutation known to cause imatinib
resistance.
- Inability to swallow tablets.
- Arterial thrombotic or ischaemic events, such as cerebrovascular accident or pulmonary
embolism within 6 months prior to randomisation; or major venous thrombotic events
requiring use of an anticoagulant such as warfarin within 6 months prior to
randomisation.
- Poorly controlled hypertension (systolic blood pressure > 140 mmHg or diastolic
pressure > 90 mmHg despite optimal medical management).
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to randomisation, or non healing wound, ulcer or fracture.
- Congestive cardiac failure (NYHA = grade 2), unstable angina or new onset angina
within the previous 3 months, or AMI within the previous 6 months. Cardiac arrhythmias
requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
- Haemorrhage or bleeding event = Grade 3 according to CTCAE v4.0 within 4 weeks prior
to randomisation.
- Ongoing infection of > Grade 2 according to CTCAE v4.0.
- Active hepatitis B or C or HIV, or chronic hepatitis B or C requiring treatment with
antiviral therapy. Testing for these is not mandatory unless clinically indicated.
- Interstitial lung disease with ongoing signs and symptoms.
- Persistent proteinuria of = Grade 3 (>3.5g/24 hours) according to CTCAE v4.0
- Other significant medical or psychiatric condition judged by the investigator to
interfere with protocol requirements.
- Use of biological response modifiers such as granulocyte colony stimulating factor
(G-CSF), within 3 weeks prior to randomisation.
- Patients taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg clarithromycin,
indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole,
ritonavir, saquinovir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg
carbamazepine, phenobarbitol, phenytoin, rifampicin, St John's wort).
- History of another malignancy within 5 years prior to registration. Patients with a
past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the
skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma
of the bladder are eligible. Patients with a history of other malignancies are
eligible if they have been continuously disease free for at least 5 years after
definitive primary treatment.
- Pregnancy, lactation, or inadequate contraception. Women must be post menopausal,
infertile, or use a reliable means of contraception. Women of childbearing potential
must have a negative pregnancy test done within 7 days prior to registration. Women of
childbearing potential and men must agree to use adequate contraception before
entering the trial until at least 8 weeks after the last study drug administration.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2023
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
78
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Canberra Hospital - Canberra
Query!
Recruitment hospital [2]
0
0
Calvary Mater Newcastle Hospital - Newcastle
Query!
Recruitment hospital [3]
0
0
Prince of Wales Hospital - Sydney
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment hospital [5]
0
0
Ashford Cancer Centre Research - Adelaide
Query!
Recruitment hospital [6]
0
0
Flinders Medical Centre - Adelaide
Query!
Recruitment hospital [7]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [8]
0
0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Query!
Recruitment hospital [9]
0
0
Border Medical Oncology - Wodonga
Query!
Recruitment hospital [10]
0
0
Sir Charles Gairdner - Perth
Query!
Recruitment postcode(s) [1]
0
0
2606 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
2310 - Newcastle
Query!
Recruitment postcode(s) [3]
0
0
2031 - Sydney
Query!
Recruitment postcode(s) [4]
0
0
4120 - Brisbane
Query!
Recruitment postcode(s) [5]
0
0
5037 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
5042 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
7001 - Hobart
Query!
Recruitment postcode(s) [8]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [9]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [10]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Finland
Query!
State/province [1]
0
0
Helsinki
Query!
Country [2]
0
0
France
Query!
State/province [2]
0
0
Bordeaux
Query!
Country [3]
0
0
France
Query!
State/province [3]
0
0
Dijon
Query!
Country [4]
0
0
France
Query!
State/province [4]
0
0
Leon
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Paris
Query!
Country [6]
0
0
Netherlands
Query!
State/province [6]
0
0
Amsterdam
Query!
Country [7]
0
0
Norway
Query!
State/province [7]
0
0
Bergen
Query!
Country [8]
0
0
Norway
Query!
State/province [8]
0
0
Oslo
Query!
Country [9]
0
0
Singapore
Query!
State/province [9]
0
0
Singapore
Query!
Country [10]
0
0
Slovakia
Query!
State/province [10]
0
0
NSW
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Barcelona
Query!
Country [12]
0
0
Sweden
Query!
State/province [12]
0
0
Lund
Query!
Country [13]
0
0
United Kingdom
Query!
State/province [13]
0
0
Birmingham
Query!
Country [14]
0
0
United Kingdom
Query!
State/province [14]
0
0
London
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Australasian Gastro-Intestinal Trials Group
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
European Organisation for Research and Treatment of Cancer - EORTC
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Scandinavian Sarcoma Group
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
An open label randomised trial for adults with histologically confirmed measurable metastatic
GIST who have received no other treatment for metastatic disease. The study aims to determine
if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in
comparison to imatinib alone to warrant further evaluation as a first line treatment for
metastatic GIST.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02365441
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Heikki Joensuu, Professor
Query!
Address
0
0
SSG
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02365441
Download to PDF